Equillium Inc (NQ: EQ )
0.8423
+0.0813
(+10.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 12, 2024
Add to My Watchlist
Press Releases about Equillium Inc
![](https://mms.businesswire.com/media/20230322005232/en/1744398/22/1_Equillium_Logo_400x400.jpg)
![](https://mms.businesswire.com/media/20230217005036/en/1716487/22/1_Equillium_Logo_400x400.jpg)
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20230207005451/en/1706676/22/1_Equillium_Logo_400x400.jpg)
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20230113005042/en/1685074/22/1_Equillium_Logo_400x400.jpg)
![](https://mms.businesswire.com/media/20221223005200/en/1672605/22/1_Equillium_Logo_400x400.jpg)
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20221216005090/en/1667228/22/1_Equillium_Logo_400x400.jpg)
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
December 16, 2022
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20221206005379/en/1655985/4/1_Equillium_Logo_400x400.jpg)
![](https://mms.businesswire.com/media/20221114005448/en/1322078/4/Equillium_Logo.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20221110005503/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20221108005336/en/1322078/4/Equillium_Logo.jpg)
Equillium to Present at Two Upcoming Investor Conferences
November 08, 2022
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20221103005508/en/1322078/4/Equillium_Logo.jpg)
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
November 03, 2022
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20221102005418/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20221026005422/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220927005571/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220915005475/en/1322078/4/Equillium_Logo.jpg)
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20220906006103/en/824838/5/Firm_Logo-with_Investor_Law_Firm.jpg)
![](https://mms.businesswire.com/media/20220906005973/en/1322078/4/Equillium_Logo.jpg)
Equillium to Acquire Metacrine in All-Stock Transaction
September 06, 2022
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20220831005201/en/1322078/4/Equillium_Logo.jpg)
Equillium to Present at Two Upcoming Investor Conferences
August 31, 2022
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20220815005539/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220728005227/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220517005501/en/1322078/4/Equillium_Logo.jpg)
From Equillium, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20220512006021/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220512005356/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220509005146/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220425005189/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220404005294/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220323005787/en/1322078/4/Equillium_Logo.jpg)
![](https://mms.businesswire.com/media/20220323005181/en/1322078/4/Equillium_Logo.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.